Stock 300294 CHINA RESOURCES BOYA BIO-PHARMACEUTICAL GROUP CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Company China Resources Boya Bio-pharmaceutical Group Co.,Ltd

Equities

300294

CNE100001FF1

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
31.37 CNY -1.07% Intraday chart for China Resources Boya Bio-pharmaceutical Group Co.,Ltd +1.23% -6.86%
Apr. 23 China Resources Boya Bio-pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 14 CR Boya Bio-Pharmaceutical's 2023 Profit Falls on Lower Revenue MT

Business Summary

China Resources Boya Bio-pharmaceutical Group Co Ltd, formerly Boya Bio-pharmaceutical Group Co Ltd, is a China-based company principally engaged in the research, development, production and distribution of blood products. The Company's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The Company's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The Company also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The Company distributes its products mainly in domestic market.

Number of employees: 1,444

Sales per Business

CNY in Million2022Weight2023Weight Delta
Blood Products
54.7 %
1,315 47.7 % 1,452 54.7 % +10.41%
Drug Distribution
28.6 %
814 29.5 % 758 28.6 % -6.93%
Biochemical Pharmaceutical
12.6 %
438 15.9 % 335 12.6 % -23.51%
Diabetes Medicine
3.7 %
178 6.5 % 97 3.7 % -45.38%
Other
0.4 %
13 0.5 % 10 0.4 % -24.36%

Sales per region

CNY in Million2022Weight2023Weight Delta
China
100.0 %
2,759 100.0 % 2,652 100.0 % -3.87%

Managers

Managers TitleAgeSince
Xiao Ming Liang CEO
 Chief Executive Officer 57 93-11-05
Hua Cheng Liang DFI
 Director of Finance/CFO 42 21-08-31
Zhen Rao BRD
 Director/Board Member 56 93-11-05
Dong Ke Peng IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Wei Dong Zhang BRD
 Director/Board Member 61 21-02-02
Xiao Ming Liang CEO
 Chief Executive Officer 57 93-11-05
Zhen Rao BRD
 Director/Board Member 56 93-11-05
Gui Ling Tan BRD
 Director/Board Member 57 15-01-13
Hua Sheng Huang BRD
 Director/Board Member 55 21-02-02
Na Tang CHM
 Chairman 48 21-12-26
Hua Cheng Liang DFI
 Director of Finance/CFO 42 21-08-31
Li Zhao BRD
 Director/Board Member 67 21-02-02

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 504,248,738 81,924,837 ( 16.25 %) 0 16.25 %

Shareholders

NameEquities%Valuation
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
16.28 %
69,331,978 16.28 % 276 M ¥
Shenzhen GTJA Investment Group Co., Ltd.
13.39 %
57,049,640 13.39 % 227 M ¥
Zhong Ou Asset Management Co., Ltd
5.085 %
21,657,140 5.085 % 86 M ¥
Jian Xin Xu
4.469 %
19,037,022 4.469 % 76 M ¥
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)
4.237 %
18,045,569 4.237 % 72 M ¥
Xin Xi Liao
2.515 %
10,714,286 2.515 % 43 M ¥
E Fund Management Co., Ltd.
0.9626 %
4,100,229 0.9626 % 16 M ¥
Yuan Yuan
0.9261 %
3,944,627 0.9261 % 16 M ¥
Huatai-PineBridge Fund Management Co., Ltd.
0.8290 %
3,531,151 0.8290 % 14 M ¥
Penghua Fund Management Co., Ltd.
0.6760 %
2,879,200 0.6760 % 11 M ¥
NameEquities%Valuation
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
100.00 %
78,308,575 100.00 % 311 M ¥

Company contact information

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

333, Huiquan Road High-tech Industrial Develop Zone

344000, Fuzhou

+86 79 4822 4549

http://www.china-boya.com
address China Resources Boya Bio-pharmaceutical Group Co.,Ltd(300294)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Ratings for China Resources Boya Bio-pharmaceutical Group Co.,Ltd

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
31.37 CNY
Average target price
34.45 CNY
Spread / Average Target
+9.81%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CHINA RESOURCES BOYA BIO-PHARMACEUTICAL GROUP CO.,LTD Stock China Resources Boya Bio-pharmaceutical Group Co.,Ltd
-6.86% 2.18B
CSL LIMITED Stock CSL Limited
-4.66% 87.53B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.63% 40.42B
BIOGEN INC. Stock Biogen Inc.
-21.76% 29.48B
UCB Stock UCB
+57.29% 25.43B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.78% 15.59B
INCYTE CORPORATION Stock Incyte Corporation
-18.49% 11.49B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-15.61% 11.1B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.02% 11.3B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.64% 8.75B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 300294 Stock
  4. Company China Resources Boya Bio-pharmaceutical Group Co.,Ltd